( smn;9.0 to 153.2±8.9 mmHg; basel...)Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension,Health

smn;9.0 to 153.2±8.9 mmHg; baseline vs. end of treatment). Diastolic blood pressure was also significantly reduced by 9.8 mmHg from 91.3±7.8 to 81.5±8.2 mmHg (p<0.001) in the SPP635 treated group compared to the placebo treatment (95.3±5.1 to 93.3±5.4 mmHg). These blood pressure measurements were taken at trough, 24 hours after the previous medication. Similar results were observed for ambulatory blood pressures, which were reduced both during the day as well as in the night.

The half-life of SPP635 had been previously reported to be approximately 24 hours suggesting once daily administration; these latest ambulatory blood pressure data confirm the use as of SPP635 as an once-a-day drug. The extent of blood pressure reduction is similar to those reported for the renin inhibitor SPP100 (aliskiren,Tekturna/Rasilez)[4].

Hans R. Brunner, Professor Emeritus of Medicine at the University of Lausanne, and acting Speedel Medical Director, commented: "These positive results show that SPP635 has comparable efficacy to other blood pressure lowering therapies. It will be exciting to see the first follow-on renin inhibitor to SPP100 demonstrate its potential in diabetic patients in further clinical trials."

Alice Huxley, CEO of Speedel, commented: "This success with SPP635 reinforces Speedel's strategy of building a family of renin inhibitors which can be profiled for both general and special patient populations. We continue to leverage our exceptional knowledge in renin inhibition which we believe has the potential to be the next gold standard for the treatment of different cardiovascular diseases."

Continued Phase II development
Clinical profiling of SPP635 will continue this year in special populations with a further study planned in diabetic patients with mild-to-moderate hypertension. This harder to manage patient group has been shown to respond to SPP100 to controlling blood pr
'"/>




Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
9. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
10. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
11. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting